Dostarlimab for previously treated advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency [ID3802]

£656.3K GBP

Funder	National Institute for Health Research
Recipient Organization	University of Warwick
Country	United Kingdom
Start Date	May 19, 2021
End Date	Nov 02, 2021
Duration	167 days
Number of Grantees	1
Roles	Award Holder
Data Source	Europe PMC
Grant ID	`NIHR133721`

Grant Description

To appraise the clinical and cost effectiveness of dostarlimab within its marketing authorisation for previously treated advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency.